Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Common Equity: 2023-2025

Historic Common Equity for CG Oncology (CGON) over the last 2 years, with Sep 2025 value amounting to $687.6 million.

  • CG Oncology's Common Equity rose 28.11% to $687.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $687.6 million, marking a year-over-year increase of 28.11%. This contributed to the annual value of $733.4 million for FY2024, which is 695.76% up from last year.
  • According to the latest figures from Q3 2025, CG Oncology's Common Equity is $687.6 million, which was up 2.58% from $670.4 million recorded in Q2 2025.
  • In the past 5 years, CG Oncology's Common Equity registered a high of $733.4 million during Q4 2024, and its lowest value of -$123.1 million during Q4 2023.
  • For the 3-year period, CG Oncology's Common Equity averaged around $541.4 million, with its median value being $619.6 million (2024).
  • Data for CG Oncology's Common Equity shows a peak YoY skyrocketed of 695.76% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows CG Oncology's Common Equity stood at -$123.1 million in 2023, then soared by 695.76% to $733.4 million in 2024, then rose by 28.11% to $687.6 million in 2025.
  • Its Common Equity stands at $687.6 million for Q3 2025, versus $670.4 million for Q2 2025 and $704.8 million for Q1 2025.